GlassScriptPhysician profile
Jeffrey M Rosch
NPI 1922007939
$12,103.94
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $134 · 2021: $432 · 2022: $47.53.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $10,491.90 | 2019 | |
| Csl Behring | $495.26 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $354.62 | 2019-2020 | |
| Genzyme Corporation | $342.13 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $188.00 | 2019-2022 | |
| Insmed, INC. | $74.59 | 2019 | |
| Glaxosmithkline, LLC. | $64.44 | 2019-2021 | |
| Amgen INC. | $41.59 | 2021 | |
| Kaleo, INC. | $34.24 | 2021 | |
| Biocryst US Sales Co., LLC | $17.17 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.